The UDP-glucuronosyltransferase, UGT1A1, is the critical enzyme responsible for detoxification of the potentially neurotoxic bilirubin by conjugating it with glucuronic acid. For decades, phenobarbital (PB) treatment for hyperbilirubinemia has been known to increase expression of the UGT1A1 gene in liver. We have now delineated the PB response activity to a 290-bp distal enhancer sequence (؊3483/؊3194) of the UGT1A1 gene. The enhancer contains 3 putative nuclear receptor motifs, and it was activated by the nuclear orphan receptor, human constitutive active receptor ( 
Bilirubin IX␣, one of the most toxic natural breakdown products in the body, is commonly associated with jaundice in neonates and young children. At extraordinarily high serum levels, it can cause mild to lethal neurotoxicity. On a daily basis, large amounts of the chromophore are formed in the spleen from heme salvaged from senescent red blood cells, as well as a lesser amount from the turnover of cytochrome P450. In mammals, before bilirubin can be effectively excreted by the biliary system, 1 it must be transported to and glucuronidated 2, 3 in the liver via a specific UDP-glucuronosyltransferase.
The requirements for glucuronidation of bilirubin for its excretion were first recognized from the fact that a severe unconjugated hyperbilirubinemia persists for the entire life span of Crigler-Najjar (CN) type I patients 4 and the Gunn rat, 5 both of whom totally lacking bilirubin UDP-glucuronosyltransferase activity in liver microsomes. 1 Later, less severe forms of the disease, CN type II and Gilbert's type, were found to be distinct from the CN type I when phenotypes with low levels of glucuronidating activity for the metabolite were found. [6] [7] [8] [9] Phenobarbital (PB) treatment was shown to dramatically reduce the hyperbilirubinemia in an infant with CN type II disease. 10 The chain of these events has led to the practice of treating patients whose hyperbilirubinemia was caused by clinical entities other than CN diseases with PB. Bilirubin is conjugated by the specific UDP-glucuronocyltransferase. 9 UGT1A1, the gene that codes for the human bilirubin isozyme, has been characterized in the UGT1 complex locus. 11 However, the mechanism by which PB brings about the increase in bilirubin transferase activity remains unknown.
Recently, the conserved 51-bp PB-responsive enhancer module (PBREM) has been defined in PB-inducible CYP2B genes. 12 Moreover, the nuclear receptor known as constitutive active receptor (CAR) is identified as the transcription factor that regulates PBREM in response to PB induction. 13 However, this enhancer and the CAR regulation have not been identified for the human UGT1A1 gene. The human CYP2B6 gene, not expressed in HepG2 cells, becomes activated in the cells transfected with a CAR-expression plasmid. 14 If the induction by PB of the UGT1A1 gene is regulated by a mechanism similar to that of the CYP2B6 gene, CAR-expressing HepG2 cells are an excellent system to screen for potential human genes that can be regulated by the receptor, such as UGT1A1. In this article, we characterize a CAR-mediated enhancer sequence of the UGT1A1 gene, and provide experimental consideration for the mechanism by which PB activates transcription of the gene in human liver.
MATERIALS AND METHODS
Screening Atlas Arrays. HepG2 and g2car-3 cells 14 were cultured in minimal essential medium supplemented with 10% fetal bovine serum. Total RNA was prepared from these cells using TRIZOL reagent (Life Technologies, Rockville, MD), and subsequently, mRNA was purified using an Oligotex mRNA kit (QIAGEN, Valencia, CA). Reverse transcriptase was employed to synthesize radioactive cDNA probes from the purified mRNAs, and those were hybridized to the Atlas Human cDNA Expression Array/Stress Toxicology Arrays (Clontech, Palo Alto, CA). The arrays were exposed to a Kodak X-OMAT film at Ϫ70°C for 3 days.
mRNA Levels. Reverse-transcription polymerase chain reaction (PCR) was employed to confirm differential expression of the genes identified by the screening of the Atlas arrays . The following primers were synthesized and PCR amplification was conducted on cDNA from HepG2 and g2car-3. CYP2B6: 5Ј-CACCCTAACACCCAT-GACCG-3Ј and 5Ј-GATCACACCATATCCCCCGGA-3Ј; UGT1A1: 5Ј-AGTGGATGGCAGCCACTGGCTGAGCATG-3Ј and 5Ј-CAGT-AAGTGGGAACAGCCAGACAAAAGC-3Ј; SOD3: 5Ј-TCTGCCTT-TGAGCTTCTCCTCTGCTC-3Ј and 5Ј-AAGGGGGAAGATCGTCA-GGTCAAAG-3Ј; ear-2: 5Ј-CTGGGCATCGACAACGTGTGC-3Ј and 5Ј-CGCACATACTCGGTGAGG-3Ј; IGFBP1: 5Ј-AAATGGAAGGA-GCCCTGCC -3Ј and 5Ј-ATCAAGTTATGTATGGAG-3Ј; carboxyesterase 1: 5Ј-TCAGTACCGTCCAAGCTTCTCATCAG-3Ј and 5Ј-GAGGTTGGTCCAGAAAGCTACTTC-3Ј. The expected sizes of amplified cDNAs were 276 bp, 257 bp, 318 bp, 428 bp, 409 bp, and 304 bp for CYP2B6, bilirubin UDP-glucuronosyltransferase (UGT1A1), superoxide dismutase 3 (SOD-3), ear-2, insulin-like growth factor-binding protein 1 (IGFBP1), and carboxyesterase 1, respectively. PCR was performed in 50 L on cDNA synthesized from 0.12 g total RNA using Advantage 2 PCR enzyme (Clontech) for 22 to 40 cycles. The PCR cycle consisted of 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 30 seconds.
To measure UGT1A1 mRNA level, cDNA prepared from total cellular RNA of HepG2 or g2car3 cells was subjected to quantitative real-time PCR with ABI Prism 7700 (PE Applied Biosystems, Foster City, CA), using 5Ј-GGCCCATCATGCCCAATAT-3Ј and 5Ј-TTCAAATTCCTGGGATAGTGGATT-3Ј as primers, and 6FAM-TTTTTGTTGGTGGAATCAACTGCCTTCAC-TAMRA for detection. The mRNA levels were normalized against ␤-actin mRNA determined by Pre-Developed TaqMan Assay Reagents for human ␤-actin (PE Applied Biosystems).
Cloning of 5-Flanking Region. The proximal Ϫ2.9-kbp promoter of the UGT1A1 gene was cloned 15 ; the sequence of Ϫ3.2 kbp of the promoter was reported previously. 16 To clone a further up-stream sequence of the UGT1A1 gene, primers 5Ј-CTTCATTGGGAAGGA-GCAGGGACACTACATTGAG-3Ј and 5Ј-CCTCTGCCTTGCTCTC-AAAACTCTGGGATAGAC-were designed from the 3Ј-region of immediate up-stream UGT1BP gene (accession number M84126) and the sequence within the 3.2-kbp DNA (accession number D87674), respectively. A 9-kbp DNA was amplified from HepG2 genomic DNA prepared using a QIAamp Tissue Kit (QIAGEN), LA-Taq DNA polymerase (Panvera/Takara, Madison, WI), and these primers. The amplified DNA was cloned into pCR-XL-TOPO (Invitrogen, Carlsbad, CA) and was sequenced.
Plasmids. The UA fragment was generated from pCAT/2.9 kbp, 15 and the UB-fragment was amplified from HepG2 genomic DNA with the primers 5Ј-CATAGTGGTACCACTCTGAATTTTCTGTGCCCA-3Ј and 5Ј-agtccactcgagTTTGAGGCTGCTTCTGCTGTG-3Ј, which were designed based on a reported sequence. 16 U2K, UC, UD, UE, and UF fragments were prepared from the 9-kbp DNA using convenient restriction enzymes. All these fragments were cloned into pGL3TK-firefly luciferase reporter plasmid, 14 and the U2K DNA sequence was determined (GenBank accession number AF313454). For deletion analysis of the U2K fragment, its subfragments were amplified using primers 1 to 6 and two commercially available primers, GL2 and RV3 (Promega, Madison, WI), for the plasmid, and then were cloned into pGL3-tk at the NheI and XhoI sites. The sequences of the primers were: 1) 5Ј-GTTTCCGCTAGC-GAGTTCTCTTCACCTCCT-3Ј; 2) 5Ј-GTTTCCGCTAGCTACACTAG-TAAAGGTCACTC-3Ј; 3) 5Ј-GCCTCCGCTAGCACATTCTAACGGT-TCATAAA-3Ј; 4) 5Ј-CCGTTCCTCGAGTCTTTGGTTAATCATT-TTCC-3Ј; 5) 5Ј-GTTTAACTCGAGCCCTCTAGCCATTCTGGATC-3Ј; 6) 5Ј-GTTTCCCTCGAGGACTGTTCATTGCGTGCTTA-3Ј.
Site-directed mutagenesis of NR3, gtNR1, and NR4 sites in the 290-bp DNA (Ϫ3483/Ϫ3194 of UGT1A1 gene) was performed using the Quick Change site-directed mutagenesis kit (Stratagene, La Jolla, CA). The primers used were: 5Ј-TACACTAGTAAGGCGCCCTCAAT-TCCAAGG-3Ј, 5Ј-AGAACAAACTTCGGCGCCTATATAACCTC-3Ј, and 5Ј-TGGCCAAGGGTAGGGCGCCGTGTGAACAAAG-3Ј, and the complements of these for NR4, gtNR1, and NR3. Italicized characters show the bases for the mutation.
Transient Transfection Assays. The reporter (NR1) 5 -tk-pGL3 was previously described. 17 For construction (gtNR1) 6 -tk-pGL3, 5Ј-gatcTTCTGAGTTTATATAACCTCTAG-3Ј and 5Ј-gatcCTAGAGG-TTATATAAACTCAGAA-3Ј were synthesized, annealed, and ligated. The resulting DNA was digested with BglII and BamHI and cloned into pGL3-tk. 14 Transient transfection assays using HepG2 cells and mouse primary hepatocytes were performed essentially as previously reported. 14, 17 HepG2 cells in 24-well plates were transfected with UGT1A1-luciferase reporter constructs (0.1 g/well), pCR3-hCAR expression plasmid (0.1 g/well), and pRL-SV40 plasmid (0.1 g/ well) by calcium phosphate coprecipitation. The medium was replaced after a 12-hour transfection period, and the cells were cultured for an additional 24 hours before the luciferase assay. For induction experiments, cells were pretreated with 8 mol/L of 3␣-androstenol for 30 minutes before the induction by 250 nmol/L 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) for an additional 24 hours. Luciferase activity was measured using the DualLuciferase reporter assay system (Promega), and enhancer activity was determined based on firefly luciferase activity normalized against Renilla luciferase activity of the cotransfected pRL-SV40. Primary hepatocytes prepared from males of 2-month-old Crl:CD-1(ICR)BR mice were transfected with the reporter plasmids (15 g) and pRL-SV40 (5 g) by electroporation. The transfected cells were seeded on a 24-well culture plate and incubated for 1 hour before the addition of PB. Luciferase activities were measured after 24-hour incubation using the Dual-Luciferae reporter assay system.
Gel-Shift Assays. The following sets of complementary oligonulceotides were synthesized and annealed for gel-shift assays. gtNR1: 5Ј-gatcTTCTGAGTTTATATAACCTCTA-3Ј and 5Ј-gatcTAGAGGT-TATATAAACTCAGAA-3Ј; NR4: 5Ј-gatcTAAAGGTCACTCAATTC-CAAGG-3Ј and 5Ј-gatcCCTTGGAATTGAGTGACCTTTA-3Ј; NR3: 5Ј-gatcTAGAGTTCAGTGTGAACAAAG-3Ј and 5Ј-gatcCTTTGTT-CACACTGAACTCTA-3Ј. Bases in lower-case letters were added to label the oligonucleotides with Klenow and [␣-32 P]dATP. Recombinant full-length hCAR was produced in Escherichia coli as N-terminal glutathione S-transferase fusion protein, and purified by affinity binding to gluthatione-agarose beads. The in vitro transcription/ translation TNT rabbit reticulocyte system (Promega) was used to synthesize human RXR␣. Binding assays were performed using GSThCAR (1 g) and/or hRXR␣ (1 L) as previously described. 14 For competition, a 100-fold concentration of cold oligonucleotides was added before the radioactive probes
RESULTS AND DISCUSSION
Genes Overexpressed in g2car-3 Cells. The g2car-3 cells, derived from a HepG2 cell transfected permanently with a mouse CAR (mCAR)-expression vector, express mCAR endogenously. 14 To select candidate genes that might be overexpressed in g2car-3 cells, Atlas arrays were screened using radioactive cDNAs prepared from g2car-3 and HepG2 cells as probes. Subsequently, reverse-transcription PCR (RT-PCR) was employed to confirm whether these candidate genes were, in fact, overexpressed in the g2car-3 cells (Fig. 1A) . In addition to the previously identified CYP2B6, bilirubin UDP-glucuronosyltransferase (UGT1A1), SOD-3, carboxyesterase 1, IGFBP 1, and ear-2 were found to be overexpressed in the HEPATOLOGY Vol. 33, No. 5, 2001 g2car-3 cells compared with their expression in HepG2 cells. Although the degrees of the CAR involvement in their expressions are not clear at the present time, all these genes can be used in future studies to determine the CAR-mediated trans-activation mechanisms, as well as the biological roles of CAR in vivo.
Because PB is known to induce the UGT1A1 gene in liver in vivo, 10 here we chose this gene for further characterization to identify DNA enhancer elements that can be regulated by CAR. To confirm that CAR, in fact, could regulate the expression of the UGT1A1 gene in g2car-3 cells, the cells were pretreated with a repressor of mCAR, androstenol, before induction by the most potent PB-type inducer TCPOBOP. The UGT1A1 mRNA was decreased by treatment with androstenol and was increased in TCPOBOP-induced cells (Fig. 1B and  1C) , which is reminiscent of induction of the CYP2B6 gene. 14 Thus, the UGT1A1 gene appeared to be directly regulated by CAR.
Deletion Assays. In an effort to locate the CAR-regulated enhancer element in the UGT1A1 gene, various DNA fragments generated from a 12-kbp 5Ј-flanking region of the gene were generated and placed in front of the reporter luciferase gene. These deletion constructs were examined for their enhancer activity in HepG2 cells cotransfected with hCAR-expression plasmid (Fig. 2) . Only the U2K fragment (Ϫ5193/Ϫ3092) displayed prominent enhancer activity, whereas the other DNA fragments were not activated by hCAR at all. Subsequently, further deletion assays were performed on the U2K fragment to delineate a minimal sequence that could be activated by hCAR (Fig. 3) . A full enhancer activity was associated with the 462-bp 3Ј-fragment (Ϫ3553/Ϫ3092), while the 5Ј-fragment (Ϫ5193/Ϫ3554) exhibited no activity. Within the 462-bp fragment, a middle 140-bp fragment activated the reporter gene approximately 2-fold, suggesting that this fragment may be a core of the enhancer activity. In fact, including additional 5Ј-and 3Ј-bases to the 140-bp fragment, a 290-bp fragment (Ϫ3483/Ϫ3194) was fully capable of activating the reporter gene in the cotransfected HepG2 cells.
Mutation Assays. Nucleotide sequence analysis of the 290-bp DNA revealed 3 potential nuclear receptor motifs that are each separated by about 90 bases (Fig. 4) . From the 5Ј-end, these motifs were named NR4 (DR-4 motif), gtNR1 (DR-4 motif), and NR3 (DR-3 motif), respectively. The sequence of gtNR1 is highly homologous to the NR1 site within the 51-bp PBREM conserved in the CYP2B genes. To define roles of each NR motif in hCAR-dependent activation of the 290-bp DNA, these motifs were mutated singularly or simultaneously. The mutated DNAs were constructed into luciferase reporter gene plasmids, and subjected to transient transfection assays in HepG2 cells cotransfected with the hCARexpression plasmid (Fig. 5) . Mutation of gtNR1 resulted in an 80% decrease of the CAR-dependent enhancer activity. On the other hand, single mutations of either NR4 or NR3 retained about 50% of the original activity. When all 3 motifs were simultaneously mutated, the 290-bp DNA completely lost its enhancer activity. These results indicate that gtNR1 plays the most significant role in the activation of 290-bp DNA by hCAR. Consistent with this, a mixture of GST-hCAR and in vitro-translated hRXR␣ bound to gtNR1, but not to NR3 and NR4, in gel-shift assays (Fig. 6) . Thus, gtNR1 appeared to be the only binding site of the hCAR:hRXR␣ heterodimer. In   FIG. 2 . Deletion analysis of U2K. Various subfragments were generated from the U2K DNA, constructed into luciferase reporter gene plasmid, and cotransfected with hCAR-expression vector into HepG2 cells for the determination of their transcription activity as described in Materials and Methods. Data presented are the average of 3 independent experiments Ϯ SD. Fold of activation was calculated as described in Fig. 2.   FIG. 3 . Transcription activity of various 5Ј-flanking fragments. Various fragments were generated from the 12-kbp 5Ј-flanking DNA of the UGT1A1 gene, constructed into the luciferase reporter gene plasmid, and cotransfected with hCAR-expression vector into HepG2 cells for the determination of transcription activity as described in Materials and Methods. Data presented are the average of 3 independent experiments Ϯ SD. Fold activation was calculated for each reporter construct by dividing the activity with hCAR by that without hCAR. The PBREM of the CYP2B gene was also used as a positive control for hCAR-mediated trans-activation in HepG2 cells. HEPATOLOGY Vol. 33, No. 5, 2001 addition to gtNR1, however, both NR3 and NR4 appeared to be required to confer full enhancer activity to the 290-bp DNA. Intriguingly, double mutation of NR3 and NR4 did not decrease the activity significantly lower than those already observed with the single mutations, meaning that NR3 and NR4 may not be functionally synergistic (Fig. 5) . How the 3 NR sites act together to confer the full enhancer activity to the 290-bp DNA remains an interesting question for future investigations.
PB Responsiveness. The responsiveness of the 290-bp DNA to PB was examined with 2 different systems: HepG2 cells and mouse primary hepatocytes. To examine PB responsiveness of a given CAR-mediated trans-activation in transfected cells such as HepG2, constitutive activity of this receptor must be repressed by compounds such as androstenol before PB treatment. For this purpose, the 290-bp DNA-luciferase reporter plasmid was cotransfected with either the mCAR-or hCARexpression vector into HepG2 cells (Fig. 7A) . As expected, when mCAR was cotransfected, androstenol treatment repressed the enhancer activity of 290-bp DNA, and the repressed activity was reactivated by TCPOBOP. To a lesser degree, the same repression and reactivation were also observed with hCAR. Because hCAR was better than mCAR with respect to their constitutive activation of 290-bp DNA, and once an effective repressor of hCAR has been identified, the PB response capability of hCAR may be more clearly demonstrated in the future. Nevertheless, in response to PB, both mCAR and hCAR could activate the 290-bp DNA in PB.
To obtain more direct indication for the PB responsiveness of 290-bp DNA, the same reporter plasmid was transfected into mouse primary hepatocytes, and the hepatocytes were treated with PB or saline solution for 24 hours. Subsequently, cell lysates were prepared for luciferase assays (Fig. 7B ). The treatment with PB resulted in over 5-fold induction of the 290-bp DNA-enhanced luciferase activity. This response appeared to be mediated by CAR, because the gtNR1-tk-luciferase reporter gene alone was also activated by PB treatment, although the gtNR1 responded to PB to a lesser extent compared with the 290-bp DNA or the NR1 of the Cyp2b10 gene. This weak response of gtNR1, however, was consistent with our finding that all 3 nuclear receptor motifs were required for conferring a full enhancer activity to the 290-bp DNA (Fig. 5) . Thus, the 290-bp DNA appeared to be an effective PB response element in mouse primary hepatocytes, and this PB response activity was mediated by CAR. We designated the 290-bp DNA the PB-responsive enhancer module of UGT1A1, or gt-PBREM.
General Discussion. The gtPBREM is a composite element consisting of 3 NR motifs and probably still-unknown cisacting sites. Like the 51-bp PBREM of CYP2B genes, gtPBREM can be regulated by the nuclear receptor, CAR, in response to PB induction. However, when gtPBREM was compared with the 51-bp PBREM of the CYP2B genes, major structural and functional differences became evident. In the PBREM, 2 NR sites (NR1 and NR2) reside close to each other, separated only by 18 bases that constitute the nuclear factor 1 binding site. There is no apparent nuclear factor 1 binding site in the gtPBREM. Three NR sites (NR4, gtNR1, and NR3) are equidistant from each other, separated by about 90 bases from the 5Ј-end of gtPBREM. The most striking difference of gtPBREM is the functional role of gtNR1, the only CAR binding site. In sharp contrast to NR1, which is a sufficient 1 element activated by CAR, gtNR1 could only be activated by the receptor in the context of 290-bp gtPBREM, and NR4 and NR3 seem to be essential for gtNR1 to confer its full enhancer activity. NR1 may be a much stronger enhancer and can be activated by CAR, whereas gtNR1 might be a weaker enhancer that requires additional factors for its activation. However, these different strengths of gtNR1 and NR1 reflect a somewhat lesser degree of PB responsiveness of the UGT1A1 gene compared with CYP2B genes. PB, with its ability to induce the UGT1A1 gene, can be an effective therapeutic drug to treat CN type II patients in whom expression of bilirubin transferase activity is low. These patients benefit from PB treatment by the increased expression of the partially active bilirubin transferase enzyme. 18 Polymorphisms have been found within the proximal region of the UGT1A1 gene, and have been associated with Gilbert's syndrome. 19 While the TATA box of the UGT1A1 gene consists of the A(TA) n TAA sequence, the TA dinucleotide is repeated 6 times in the presumed wild-type gene and 5, 7, or 8 times in "mutant" alleles. [19] [20] [21] The A(TA) 6 TAA exhibited approximately 4-fold higher transcription activity than the A(AT) 7 TAA in transient transfection assays. The A(TA) n TAA is not a PB response element, because a proximal promoter including this sequence was not capable of activating the transcription in response to PB. The distal PB response element, gtPBREM, might be able to enhance transcription activity of the weak A(TA) 7 TAA, resulting in induction of the UGT1A1 enzyme to decrease unconjugated bilirubin. In addition, mutation of gtPBREM could become a cause of hyperbiliruminemia, if the enhancer module is regulated by some endogenous factors. Such mutations might alter patient susceptibility to responding to PB treatment, as seen in some CN-type II patients. 22 The effects could be more critical for patients with an additional mutation in the coding region that produces an inefficient UGT1A1 enzyme. Finding gtPBREM polymorphisms may provide an insight into understanding the diseases, as well as developing better therapeutic methods. If such polymorphisms are identified, they would also aid in the study of the molecular mechanism that regulates gtPBREM and the UGT1A1 gene in vivo.
